Plasma ADAM-10 levels and functional outcome of acute primary basal ganglia hemorrhage

Clin Chim Acta. 2022 Jan 1:524:18-24. doi: 10.1016/j.cca.2021.11.026. Epub 2021 Nov 28.


Background: The a-secretase A disintegrin and metalloprotease-10 (ADAM-10) may have deleterious effects in acute brain injury. This study was designed to discern if a relationship between plasma ADAM-10 levels and functional outcome exists in patients with intracerebral hemorrhage (ICH).

Methods: A total of 109 patients with basal ganglia hemorrhage and 100 healthy controls were included. Their plasma ADAM-10 levels were gauged. Ninety-day prognosis was assessed and poor outcome was defined as death or major disability (modified Rankin Scale score of 3 or greater).

Results: Plasma ADAM-10 levels were substantially elevated in patients, as compared to controls. ADAM-10 levels were independently correlated with hematoma size and National Institutes of Health Stroke Scale (NIHSS) score. Plasma ADAM-10, NIHSS score and hematoma size emerged as the independent predictors for 90-day poor outcome. Under receiver operating characteristic curve, plasma ADAM-10 levels exhibited similar prognostic capability, as compared to hematoma size and NIHSS score; moreover, it significantly improved prognostic abilities of NIHSS and hematoma size.

Conclusions: Rising plasma ADAM-10 levels are independently related to increasing severity and poor long-term functional outcome after hemorrhagic stroke, substantializing serum ADAM-10 as a useful prognostic biomarker of ICH.

Keywords: A disintegrin and metalloprotease 10; Intracerebral hemorrhage; Outcome; Severity.

MeSH terms

  • Basal Ganglia Hemorrhage* / diagnosis
  • Cerebral Hemorrhage / diagnosis
  • Graft vs Host Disease*
  • Hematoma
  • Humans
  • Prognosis